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Background: Maintenance therapy with imatinib during the post-transplant period has been used for patients with
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy has not been
demonstrated. A study was designed to investigate the safety of imatinib and its efficacy in preventing
hematological relapse and improving disease-free survival (DFS) when administered after allogeneic hematopoietic
stem cell transplantation (allo-HCT).
Methods: Patients with Ph +ALL that received allo-HCT were enrolled in the study. Real-time quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) was used to detect BCR-ABL transcript levels. Imatinib therapy
was initiated if patient neutrophil counts were> 1.0 × 109/L and platelet counts were> 50.0 × 109/L, or if they
displayed either elevated BCR-ABL transcript levels in two consecutive tests, or a BCR-ABL transcript level≥ 10-2 after
initial engraftment. Patients receiving imatinib after relapse were assigned to the non-imatinib group. The imatinib
treatment was scheduled for 3–12 months, until BCR-ABL transcript levels were negative at least for three
consecutive tests or complete molecular remission was sustained for at least 3 months.
Results: A total of 82 patients were enrolled. Sixty-two patients initiated imatinib therapy post-HCT. Imatinib
therapy was initiated at a median time of 70 days post-HCT. Grade 3–4 adverse events (AEs) occurred in 17.7% of
patients. Ten patients (16.1%) terminated imatinib therapy owing to AEs. Among the patients in imatinib and non-
imatinib groups, the estimated 5-year relapse rate was 10.2% and 33.1% (p = 0.016), and the 5-year probability of
DFS was 81.5% and 33.5% (p = 0.000) with the median follow-up of 31 months (range, 2.5-76 months) and
24.5 months (range, 4–72 months), respectively. Multivariate analysis identified imatinib maintenance therapy post-
HCT as an independent prognostic factor for DFS (p = 0.000, hazard ratio [HR] =4.8) and OS (p = 0.000, HR = 6.2).
Conclusions: These results indicate that relapse rate can be reduced and DFS may be improved in Ph + ALL
patients with imatinib maintenance therapy after HCT. BCR-ABLmonitoring by qRT-PCR can guide maintenance
therapy with imatinib including initiation time and treatment duration after allo-HCT.* Correspondence: Huangxiaojun@bjmu.edu.cn
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Allogeneic hematopoietic stem cell transplantation (allo-
HCT) is still considered the optimal curative treatment for
Philadelphia chromosome-positive acute lymphoblastic
leukemia (Ph+ALL). The disease-free survival (DFS) of
Ph+ALL patients after allo-HCT ranges from 21% to 57%
[1-4]. The main cause of treatment failure is relapse, and
approximately 30% of patients that undergo allo-HCT in
first complete remission (CR1) eventually relapse. Of the
patients that undergo allo-HCT beyond CR1, or for those
with refractory disease, the relapse rate is even higher. The
tyrosine kinase inhibitor, imatinib, has been widely used
for the treatment of chronic myelogenous leukemia [5,6],
and has recently been used for treatment of Ph+ALL.
Since the introduction of imatinib in the combination
chemotherapy regimes for newly diagnosed Ph+ALL,
more than 95% of patients can achieve CR1. Several stud-
ies have shown decreased relapse rates and improved DFS
for patients with imatinib-based treatment prior to allo-
HCT, compared with their historical controls [7-9]. How-
ever, the efficacy of maintenance therapy with imatinib
after transplant for Ph+ALL patients is still uncertain.
Detection of minimal residual disease (MRD) after
transplant is associated with an increased risk of relapse
[10]. An early study by Wassmann et al showed that
MRD-triggered imatinib therapy led to complete mo-
lecular remission (CRmol) in 52% of patients expressing
BCR-ABL after HCT; however, approximately 50% of
patients ultimately experienced hematological relapse
[11]. In addition, it was reported that 23% of Ph +ALL
patients that screened negative for BCR-ABL after allo-
HCT relapsed [12]. Thus, earlier initiation of imatinib
treatment in the setting of low leukemia burden, or
negative detection of MRD after HCT, may reduce the
relapse rate and improve survival to an even greater ex-
tent. The feasibility and safety of early prophylactic ad-
ministration of imatinib after HCT has been previously
confirmed [13]. However, imatinib toxicity is relevant
when started soon after HCT.
We previously demonstrated that administration of
imatinib in the first 90 days after allo-HCT, based on
MRD monitoring, is feasible, and the toxicity is accept-
able. Preliminary results showed that treatment outcome
was significantly improved compared with our previous
study [4]. In this phase II study, we evaluated the safety
and efficacy of imatinib therapy, when initiating treat-
ment based on patient clinical conditions and BCR-ABL
transcript levels after allo-HCT. We also investigated the
factors that may impact relapse and survival.Materials and methods
Patient eligibility
Allo-HCT recipients diagnosed with Ph+ALL (< 60 years
of age) were eligible for the study, regardless of the source
of HCT (from either HLA-matched sibling donors, unre-
lated donors or mismatched related donors). The diagno-
sis of Ph+ALL was based on the WHO diagnosis criteria.
Patients were excluded from the study if they displayed
hypersensitivity or were assessed as resistant to imatinib
before HCT. Patients were also excluded if either
hematological relapse or extramedullary leukemia involve-
ment was diagnosed after initial engraftment, or if the life
expectancy was less than 1 month post-HCT. The study
was reviewed and approved by the ethics committee at Pe-
king University People’s Hospital. All patients provided
written, informed consent before transplantation.
Conditioning regimen and graft-versus-host disease
(GVHD) prophylaxis
All patients received a myeloablative transplant. Condi-
tioning regimens were as previously described [14,15]. In
matched sibling transplants, the conditionings were (1)
total body irradiation (TBI) with 7.7-12.0 Gy and cyclo-
phosphamide (Cy) 1.8 g/m2/d × 2 days or (2) hydroxyurea
(40 mg/kg, q12 h) given on day −10, cytosine arabinoside
(Ara-C, 2 g/m2/d) intravenously on day −9; busulfan
(Bu,3.2 mg/kg per day) intravenously on days −8 to −6; Cy
(1.8 g/m2/d) intravenously on days −5 and −4; Methyl-N-
(2-chloroethyl)-N-cyclohexyl-N-nitrosourea (Me-CCNU,
250 mg/kg/d) orally once on day −3. Patients that under-
went mismatched related and unrelated HCT were given
cytosine arabinoside (2–4 g/m2/d) on days −10 and −9 in
the Bu/Cy regimen (as shown above) and anti-human
thymocyte globulin (ATG, 2.5 mg/kg/d,Sang Stat, Lyon,
France) intravenously for 4 consecutive days from days −5
to −2.
All transplant recipients received cyclosporin A-based
acute GVHD prophylaxis [14,15]. Supportive care was
administered as previously described [14].
MRD assessment
The level of BCR-ABL transcripts in patient bone mar-
row was assessed by TaqMan-based real-time quantita-
tive reverse-transcription polymerase chain reaction
(qRT-PCR), as previously described [16]. The BCR-ABL
primers and probe that amplify both the b3a2 and b2a2
junctions are previously published [17]. The primers and
probe that amplify the ABL and e1a2 BCR-ABL junc-
tions are listed in the report of the Europe against
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calculated as: fusion transcript copies / ABL transcript
copies × 100 (%). The ABL copy number of all the sam-
ples included in this study was greater than 3 × 104. The
reproducible sensitivity of qRT-PCR was five copies. A
CRmol was defined as the negative expression of BCR-
ABL by qRT-PCR in patient bone marrow specimens.
Bone marrow aspiration for morphological and cytogen-
etic analysis (fluorescence in situ hybridization, FISH),
flow cytometry and qRT-PCR was scheduled for 1, 3, 6,
9 and 12 months post-HCT (qRT-PCR tests were
repeated at 2-week intervals if necessary), then once
every 6 months between months 12 and 24 post-HCT.Study design and treatment
Treatment with imatinib was initiated: (1) if patient per-
ipheral blood absolute neutrophil counts (ANC) were
>1.0 × 109/L without granulocyte colony-stimulating fac-
tor (G-CSF) administration, and the platelet count was
>50.0 × 109/L, regardless of the level of BCR-ABL tran-
script; or (2) if the level of BCR-ABL transcript in the
bone marrow was detectable and transcript levels
increased for two consecutive tests, or if the BCR-ABL
transcript level was ≥10-2 after the initial engraftment,
although patients ANC or platelet count were below the
above values. Other criteria for initiation of treatment
included that patients could tolerate oral imatinib with-
out gut GVHD or life-threatening infection.
Imatinib treatment was scheduled for 3–12 months
after HCT, until BCR-ABL transcript levels were negative
at least for 3 consecutive tests or CRmol was sustained
for at least 3 months, as described in our previous report
[19].
The initial dose of imatinib was 400 mg/d for adults (>
17 years) and 260 mg/m2/d for children (< 17 years). The
daily dose of imatinib was adjusted according to the Na-
tional Comprehensive Cancer Network practice guideline
regarding the management of imatinib toxicity (version
2005). The dose of imatinib was reduced to 300 mg/d if
the ANC was <1.0 × 109/L, despite administration of G-
CSF, or if the platelet count was less than 20× 109/L. The
dose of imatinib could escalate to 600 mg/d (340 mg/m2/d
in children <17 years). The minimum acceptable dose of
imatinib was 300 mg/d (260 mg/m2/d for children
<17 years) for at least 5 days per week.
Patients were permitted to voluntarily withdraw from
the study at any time or were withdrawn if grade 3 or 4
toxicity was sustained for more than 2 weeks, despite
interrupting the imatinib therapy.Safety and efficacy
The primary study end point addressed patient safety.
The toxicity of imatinib was assessed according to theCommon Toxicity Criteria, version 3.0. The secondary
study endpoint assessed the efficacy of imatinib therapy.
The efficacy evaluation included relapse rate, DFS and
overall survival (OS). A post-transplant relapse was
defined as hematological relapse, extramedullary involve-
ment of leukemia and cytogenetic relapse. DFS was
defined as continuous survival without relapse or death
from any cause after HCT. OS was defined as continu-
ous survival until death from any cause after HCT.
Patients who were treated with imatinib for less than
7 days were not included for the efficacy evaluation, but
were included in the safety evaluation.
Statistical analysis
Parametric tests used the χ2 test or Fisher’s exact test.
The Mann–Whitney U test was used for nonparametric
tests. Univariate analysis for DFS and OS of all enrolled
patients was conducted using Kaplan-Meier analysis
with the log-rank test. The factors included in the uni-
variate analysis were sex, age (> 30/< 30 years), disease
status pre-HCT (CR1/> CR1), BCR-ABL transcript levels
before and after HCT, donor type, acute and chronic
GVHD, imatinib therapy versus no treatment, post-HCT
. Multiple regression analysis for DFS and OS was con-
ducted using multiple Cox regression. The covariates
adjusted in the multiple regression models included fac-
tors identified as significant in the univariate analysis (p
< 0.05). Kaplan-Meier analysis was used to estimate DFS
and OS, while cumulative incidence was calculated for
non-relapse mortality (NRM) and relapse rate. The re-
lapse rate was also calculated by taking into account the
competing risk of death due to other complications
using the Fine-Gray model. The log-rank test was used
to compare the survival curve and the Gray test for cu-
mulative incidence curve between the imatinib and non-
imatinib groups. Data analysis was performed using the
SPSS and R software packages, and a p-value< 0.05 was
considered statistically significant.
Results
Patient enrollment and engraftment
From May 2005 to March 2010, 82 patients (median
age, 28.5 years; range, 3–51 years) consented to partici-
pate in the study. The demographic characteristics and
relevant transplantation data for these individuals are
shown in Table 1. Imatinib therapy was initiated in 62
patients, according to the study regimen. Within this
group, two patients received imatinib therapy for less
than 7 days, owing to severe gut GVHD and grade 3
hematologic toxicity, respectively, and thereafter were
not included in the efficacy evaluation. Twenty patients
did not receive imatinib therapy for the following rea-
sons: pancytopenia (n = 2), severe infections (n = 6), se-
vere gut GVHD (n = 7) or personal decisions (n = 5).
Table 1 Patient characteristics in the imatinib and non-
imatinib groups
Imatinib group Non-imatinib group P-value
Number of patients 62(75.6%) 20(24.4%)
Age (y), median (range) 29(6-50) 27.5(3-51) 0.256
<30 / >30 y 37/25 10/10 0.604
Sex (M/F) 43/19 12/8 0.071
Disease status pre-HCT
CR1/ >CR1 50/12 16/4 1.000
Additional cytogenetic
abnormality
Yes/No 3/59 1/19 0.272
Imatinib therapy
before HCT
Yes/ No 54/8 14/6 0.180
RT-PCR-BCR/ABL
(pre-HCT)
0/ >0 26/36 6/14 0.752
Donor type




PBSCT 7 2 1.000
BMT+ PBSCT 55 18
Conditioning regimen











0/ >0 48/ 14 18/ 2 0.540
Acute GVHD
0/ I°-II°/ III-IV° 30/ 28/ 4 5/ 11/ 4 0.199
Chronic GVHD
no/ L/ E-cGVHD 22/ 25/ 12 3/ 8/ 8 0.223
CR1, first complete remission; MMR, mismatched related; MUD, matched
unrelated donor; BMT, bone marrow transplant; PBSCT, peripheral blood stem
cell transplant; L, local; E-cGVHD, extensive chronic GVHD.








0 1-2 3 4
Hematology 36 26 32 3 1
Neutropenia 36 26 32 2 2
Thrombocytopenia 36 26 34 1 1
Edema 19 43 16 3 0
Nausea/emesis 29 33 24 4 1
Elevation of ALT/AST 3 59 3 0 0
AEs, adverse events.
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HCT. All patients, except one, achieved platelet engraft-
ment. The engraftment time was not significantly differ-
ent between the imatinib and non-imatinib groups
(Table 1).
Imatinib treatment and safety
All enrolled patients achieved hematological remission
and all of them were in complete cytogenetic remission(CCyR) following myeloid engraftment. Treatment with
imatinib was initiated at a median time of 70 days post-
HCT (range, 20–270 days), and the median duration of
imatinib therapy was 90 days (range, 13–540 days).
Thirty-four adult patients tolerated imatinib at a daily
dose of 400 mg. The daily dose of imatinib was
decreased to 300 mg in 16 adults for 5–7 days a week.
Seven out of 10 children tolerated imatinib at a daily
dose of 260 mg/m2.
Sixty-two patients were included in the safety evalu-
ation, including both hematological and non-
hematological toxicities (Table 2). Of these, 44 patients
(70.9%) experienced different adverse events (AEs) that
were possibly due to imatinib therapy. Two, simultaneous
AEs were observed in 28 patients. Grade 3–4 AEs oc-
curred in 11 (17.7%) patients, and were all reversible. Ten
patients (16.1%) treated with imatinib for less than
3 months, terminated treatment because of AEs (n= 9) or
gut GVHD (n=1).Response to imatinib therapy and outcome after HCT
After HCT, the bcr-abl tests by qRT-PCR were negative in
48 patients prior to administration of imatinib. Within this
group, hematological relapse occurred in 4 patients (1
received imatinib for less than 7 days after HCT) and
extramedullary leukemia relapse occurred in one patient.
These five patients received other treatment option in
addition to imatinib, including chemotherapy or irradi-
ation, followed by donor lymphocyte infusion (DLI). Of
this group, two patients died from relapse and two
patients died from non-relapse complications.
Prior to imatinib therapy, 14 patients tested positive
for BCR-ABL expression following engraftment. Eight
patients became BCR-ABL negative 1 month after imati-
nib therapy (range, 1–3 months). Two patients died
from hematological relapse. Four patients displayed per-
sistent BCR-ABL expression for 3 months and achieved
CRmol with additional treatment such as chemotherapy
plus DLI, second-generation tyrosine kinase inhibitors,
or secondary allo-HCT. Four patients died from non-
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(n = 2); demyelinating polyneuropathy (n = 1) or post-
transplant lymphoproliferative disease (n = 1).
In the non-imatinib treated group, five patients died
from hematological relapse. One patient with central ner-
vous system relapse survived in complete remission after
receiving central nervous system irradiation and imatinib
therapy. The causes of non-relapse death included GVHD
(n=1), infection (n= 3) and others (n= 3).Relapse rates and NRM
At the time of the last follow-up (November 2011), a
total of 13 patients had relapsed, including
hematological relapse (n = 11) or extramedullary
leukemia relapse (n = 2). No cytogenetic relapse occurred
without hematological relapse concurrently. The overall
5-year relapse rate was 18.34 ± 4.8%. The estimated 5-
year probability of relapse between the imatinib and
non-imatinib treated groups was 10.2%± 3.9% and
33.1%± 10.8% (p = 0.016), respectively (Figure 1). The
median time of relapse was 9.5 months (range, 2.5-
17.5 months) in the imatinib group of patients, post-
HCT. The median time of relapse was 12 months (range,
3–22 months) in the non-imatinib group of patients.
Three patients experienced molecular relapse at 6, 12
and 18 months after terminating imatinib treatment. All
three patients achieved a second CRmol following re-
administration of imatinib for 1 month. The NRM
among the imatinib group and non-imatinib group wasFigure 1 Cumulative incidence of relapse for patients in imatinib and
taking into account the competing risk of death due to other complication
imatinib compared with non-imatinib treated groups (10.18% vs 33.05%, p6.66%± 3.24% and 37.19%± 10.89% (p = 0.0006),
respectively.DFS and OS
At the time of the last follow-up (November 2011), 52/62
patients in the imatinib group were alive at a median
follow-up of 31 months (range, 2.5-76 months). All
patients were in CRmol without imatinib administration.
The median time of discontinuation of imatinib therapy
was 26 months. In contrast, only 8/20 patients in the non-
imatinib group were alive at a median follow-up of
24.5 months (range, 4–72 months). The overall 5-year
DFS and OS for all patients was 68.9%±5.2% and
71.0%±5.6%, respectively. The estimated probabilities of
DFS and OS at 5 years was 81.5%±5.0% and 86.7%±4.4%
for the imatinib group, respectively, compared with
33.5%±10.6% and 34.3%±10.5% for the non-imatinib
group (p= 0.000 and 0.000) (Figures 2 and 3).Prognostic factors associated with DFS and OS
Univariate analysis revealed that post-HCT mainten-
ance therapy with imatinib treatment, pre-HCT dis-
ease status and pre-HCT BCR-ABL transcript levels
were significant factors impacting DFS and OS
(p = 0.000, 0.013, 0.020, respectively).
By multivariate Cox regression analysis, post-HCT
imatinib maintenance therapy was identified as an in-
dependent prognostic factor for DFS and OS (Table 3).Imatinib group 
Non-imatinib group 
non-imatinib groups, post-HCT. The relapse rate was calculated by




Figure 2 Disease-free survival (DFS) at 5 years in imatinib and non-imatinib groups, post-HCT. Kaplan-Meier analysis showed that the 5-
year DFS of patients in the imatinib-group was significantly higher than in the non-imatinib group (81.5% vs 33.5%, p = 0.000).
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Until now, there have been no large, controlled studies
demonstrating that imatinib therapy after HCT can im-
prove DFS. A small non-randomized, single-center study
from Minnesota identified a trend toward decreased re-
lapse rate in patients treated with imatinib in the pre-
and/or post-transplant period [20]. However, only two
patients in their study were treated with imatinibImatinib group 
       Non-imatinib
Figure 3 Overall survival (OS) at 5 years in imatinib and non-imatinib
of patients in the imatinib-group was significantly higher than the patientsmaintenance therapy post-transplant. The reports from
the Children’s Oncology Group recently showed that
patients receiving imatinib therapy for 6 months following
matched sibling donor HCT (n=19) showed no advantage
in 3-year event-free survival (EFS) compared with bone
marrow transplantation (BMT) alone [21,22].
We administered imatinib maintenance therapy for
Ph +ALL patients after HCT based on patient clinicalgroups, post-HCT. Kaplan-Meier analysis showed that the 5-year OS
in the non-imatinib group (86.7% vs 34.3%, p = 0.000).
Table 3 Multivariate analysis of factors associated with
DFS and OS
Variable DFS OS
HR 95% CI P HR 95% CI P
non-IM use post-HCT 4.8 2.2-10.8 .000 6.2 2.6-15.0 .000
> CR1 pre-HCT 2.7 1.1-6.6 .023
BCR-ABL(+) pre-HCT 3.7 1.3-10.5 0.014
IM, imatinib; HR, hazard ratio; CI, confidence interval.
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demonstrates for the first time that patients treated with
imatinib maintenance therapy post-HCT have a lower
relapse rate and a survival advantage in term of DFS and
OS, compared with non-imatinib treated patients. The
limitation to this study was that patients in our trial
were not randomized to receive imatinib therapy post-
HCT. In addition, more patients died from non-relapse
complications in the non-imatinib group compared with
the imatinib treated group, which may impact the out-
come. It should be noted, however, that the demographic
characteristics and certain relevant transplant data were
similar between the two patient groups (except for 3
patients receiving TBI/Cy as conditioning regimen in the
non-imatinib group), thus allowing for a comparison.
Multivariate analysis of all enrolled patients also showed
that imatinib maintenance therapy post-HCT was an in-
dependent prognostic factor for DFS. Additional care-
fully designed or randomized studies with large patient
cohorts are required, however, to confirm the efficacy of
this strategy.
The optimal time for initiating imatinib treatment
post-HCT is not well established. Previous studies have
shown that the ability of patients to tolerate imatinib
therapy decreases in cases of poor engraftment and
GVHD reactions following HCT. Early initiation of ima-
tinib is frequently associated with grade 3 or 4 cytopenia
in the first 100 days after allo-HCT [23]. A study in
which all patients were anticipated to begin imatinib
treatment (400 mg/day) from the time of full
hematological recovery after HCT showed that 12 of 21
patients initiated imatinib at a median time of 3.9 months
post-HCT; however, treatment was interrupted in 10
patients owing to complications such as GVHD [24].
Thus, early initiation of imatinib treatment in patients,
regardless of their clinical conditions following allo-HCT
, may be limited by transplant-related complications and
drug toxicity. A recent multi-center, randomized trial by
Pfeifer et al revealed no significant difference in OS be-
tween patients with pre-emptive imatinib therapy and
those with prophylactic administration of the drug after
HCT [25]. In this study, more than half of enrolled
patients discontinued imatinib therapy in both groups of
patients, predominantly owing to gastrointestinaltoxicities [25]. These data suggest that there are still lim-
itations in the initiation of imatinib therapy just based
on post-HCT BCR-ABL transcript levels. Furthermore,
imatinib therapy may not need to be initiated at the
same time period after HCT in patients with negativity
for BCR-ABL expression. This report also showed that
detection of BCR-ABL transcripts within 100 days of
transplant is associated with a significantly inferior EFS,
despite rapid initiation of imatinib treatment [25]. This
indicates that delayed initiation of imatinib therapy after
HCT may decrease the efficacy of imatinib therapy for
some patients.
Our trial was designed to initiate imatinib therapy
based on patient BCR-ABL transcript levels, while con-
currently taking into account the clinical conditions of
individual patients (including blood cell counts, GVHD).
Grade 3–4 AEs and interruption of imatinib therapy due
to AEs or gut GVHD were relatively low compared with
other reports [23-25]. Therefore, we conclude that our
treatment strategy balanced the safety and efficacy of
imatinib therapy after allo-HCT.
MRD positivity pre- and post-HCT is reported to be
associated with a high relapse rate after HCT [10,12]. In
our study, we found that detection of BCR-ABL expres-
sion pre-HCT had a significant adverse impact on DFS.
This is in line with recent studies showing that MRD
levels at different time points prior to HCT have prog-
nostic relevance, and that lower levels of MRD prior to
HCT are associated with better DFS following allo-HCT
[26,27].
To date, there is no defined period of administering
imatinib therapy post-HCT that has been demonstrated
to be more appropriate for reducing relapse rate and im-
proving survival. Most studies suggest arbitrarily using
imatinib therapy for 6 months to 1 year after allo-HCT,
or for 1 year after the first documentation of BCR-ABL
negativity post-HCT [11,22]. However, in these studies
patients still experienced molecular relapse or even
hematological relapse after termination of imatinib treat-
ment. Sustained CRmol is defined by some researchers as
BCR-ABL negativity lasting for a period of at least
3 months [28]. Our regimen was designed to use imati-
nib until BCR-ABL transcripts were negative at least for
3 consecutive tests or CRmol was sustained for at least
3 months. Our preliminary results showed that the re-
lapse rate was lower and DFS was higher compared with
our previous studies (DFS, 37.1%) [4]. These data sup-
port the rationale of our strategy, which employs regular
monitoring of BCR-ABL transcript levels by qRT-PCR to
guide the treatment period in which imatinib therapy
should be administered after HCT. Other factors such as
graft-versus leukemia effect may also contribute to eradi-
cating MRD when combined with imatinib therapy after
allogeneic transplant. We are aware, however, that the
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studies involving larger patient cohorts with a longer
follow-up period are needed to accurately define the
time period of imatinib therapy post-HCT.
Our study also showed that the remission status at the
time of HCT significantly predicted OS. Thus, patients
transplanted in CR1 had significantly higher OS rates com-
pared with those transplanted in>CR1. These data are
supported by other studies involving both matched-
related and unrelated donors for both adults and children
with either Ph-ALL or Ph+ALL [29-31]. Therefore, we
still recommend that patients with Ph+ALL undergo allo-
HCT in CR1 if they have available donors.
Conclusions
In summary, our study demonstrates that relapse rate can
be reduced and DFS may be improved in Ph+ALL patients
using imatinib maintenance therapy. BCR-ABL monitoring
by qRT-PCR can well guide imatinib therapy including ini-
tiation time and duration of treatment after HCT. Even in
the imatinib era, Ph+ALL patients with available donors
will benefit from receiving allo-HCT in CR1.
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